Enlarge image
Biontech warehouse in Mainz: The company confirmed its forecast for the full year 2022
Photo: Sebastian Gollnow / dpa
The Mainz-based company Biontech continues to benefit greatly from the great demand for its corona vaccine.
In the first half of the year, Biontech had sales of 9.6 billion euros and a profit of 5.4 billion euros, as the company announced on Monday.
For the year as a whole, Biontech is aiming for sales of EUR 13 billion to EUR 17 billion.
Looking at the second quarter alone, however, there was a decline in both sales and profits compared to the same period of the previous year.
The corona vaccine manufacturer attributed this to the fact that the dynamic development of the pandemic “is leading to a postponement of orders and thus to fluctuations in quarterly sales”.
The company confirmed its forecast for the full year 2022 with Covid-19 vaccine sales of 13 to 17 billion euros.
In 2021, Biontech had achieved sales of almost 19 billion euros.
Preparations for the market launch of two new vaccines adapted to the new corona variant are "in full swing," said Biontech.
The "product pipeline" also includes next-generation vaccine candidates aimed at longer and broader protection against the virus, as company boss and founder Uğur Şahin explained.
According to the announcement, a clinical study of a vaccine adapted to the omicron variants BA.4 and BA.5 is to start this month.
If the responsible authorities approve this, the first doses could be delivered from October.
Biontech had previously developed a vaccine adapted to the BA.1 variant.
The EU medicines agency EMA started the test procedure for this vaccine from the manufacturers Biontech and Pfizer in mid-June.
The EMA is also testing an adapted vaccine from the US manufacturer Moderna, which, like the vaccines from Biontech/Pfizer, is based on mRNA technology.
So far, no vaccine has been approved in the EU that also targets variants of the corona virus.
ani/dpa/Reuters
